兰索拉唑杂质H | 1346598-28-4

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 兰索拉唑杂质H
• 英文名称: Unii-MJ2A99A26H
• 英文别名: 16-(1H-benzimidazol-2-ylsulfanyl)-14-methyl-13-(2,2,2-trifluoroethoxy)-1,8,10-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-2,4,6,8,11,13,15-heptaene
• CAS: 1346598-28-4
• 化学式: C₂₃H₁₆F₃N₅OS
• 分子量: 467.5
• InChiKey: BJRFQGDDNNBKOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  85.4
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] DEXLANSOPRAZOLE PROCESS AND POLYMORPHS<br/>[FR] PROCÉDÉ DE PRÉPARATION DU DEXLANSOPRAZOLE ET AUTRES FORMES POLYMORPHES
  申请人：REDDYS LAB LTD DR

  公开号：WO2009117489A1

  公开（公告）日：2009-09-24

  Processes for the preparation of dexlansoprazole, an amorphous form of dexlansoprazole, a solid dispersion of amorphous dexlansoprazole and a pharmaceutically acceptable carrier, and processes for their preparation. Also provided are crystalline compounds 2-[(R)-[(4-chloro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and 2-[(R)-[(4-nitro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, and methods for their preparation.

  制备右旋雷贝拉唑、右旋雷贝拉唑非晶形态、非晶态右旋雷贝拉唑与药物可接受载体的固体分散体的工艺，并提供了晶体化合物2-[(R)-[(4-氯-3-甲基-2-吡啶基)甲基]亚砜基]-1H-苯并咪唑和2-[(R)-[(4-硝基-3-甲基-2-吡啶基)甲基]亚砜基]-1H-苯并咪唑以及它们的制备方法。
• DEXLANSOPRAZOLE PROCESS AND POLYMORPHS
  申请人：Kolla Naveen Kumar

  公开号：US20110028518A1

  公开（公告）日：2011-02-03

  Processes for the preparation of dexlansoprazole, an amorphous form of dexlansoprazole, a solid dispersion of amorphous dexlansoprazole and a pharmaceutically acceptable carrier, and processes for their preparation. Also provided are crystalline compounds 2-[(R)-[(4-chloro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and 2-[(R)-[(4-nitro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, and methods for their preparation.

  制备左旋埃索美拉唑、无定形左旋埃索美拉唑、无定形左旋埃索美拉唑固体分散体和药用可接受载体的制备方法。同时还提供了结晶化合物2-[(R)-[(4-氯-3-甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑和2-[(R)-[(4-硝基-3-甲基-2-吡啶基)甲基]亚磺酰基]-1H-苯并咪唑，以及它们的制备方法。
• Process for the preparation of crystalline dexlansoprazole
  申请人：DIPHARMA FRANCIS S.r.l.

  公开号：US10370359B2

  公开（公告）日：2019-08-06

  The present invention relates to a process for the preparation of anhydrous crystalline 2-(R)-[(3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl]-1H-benzimidazole (dexlansoprazole).

  本发明涉及一种制备无水结晶 2-(R)-[(3-甲基-4-(2,2,2-三氟乙氧基)-2-吡啶基)甲基)亚磺酰基]-1H-苯并咪唑（右兰索拉唑）的工艺。
• PHARMACEUTICAL FORMULATIONS OF ACID-LABILE DRUGS
  申请人：Lad Vishal

  公开号：US20110189271A1

  公开（公告）日：2011-08-04

  Pharmaceutical formulations comprising inert cores that are coated with a layer comprising an amorphous dexlansoprazole sodium salt formed in-situ, further sequentially coated with an intermediate layer and an enteric coating layer. Coated cores may be further formulated to produce tablets or capsules.
• PHARMACEUTICAL FORMULATIONS COMPRISING SUBSTITUTED BENZIMIDAZOLE DERIVATIVES
  申请人：Vaya Navin

  公开号：US20120058194A1

  公开（公告）日：2012-03-08

  Stabilized substituted benzimidazole modified release pharmaceutical formulations with at least two drug-containing fractions, wherein the release from a first fraction precedes the release from a second fraction, pharmaceutical excipients, processes for preparing the stable formulations, packaging therefor, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.